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Background. The main objective was to determine the impact of herbal drug use on adverse drug reactions in patients on
antiretroviral therapy (ART). Methodology. Patients receiving ﬁrst-line ART from the national roll-out program participated in
this cross-sectional study. Participants were interviewed and a data collection sheet was used to collect information from the
corresponding medical record. Results. The majority (98.2%) of participants were using at least one herbal drug together with
ART. The most common herbal remedies used were Allium Sativum (72.7%), Bidens pilosa (66.0%), Eucalyptus globulus (52.3%),
Moringa oleifera (44.1%), Lippia javanica (36.3%), and Peltoforum africanum (34.3%). Two indigenous herbs, Musakavakadzi
(OR = 0.25;95%CI0.076–0.828)andPeltoforumafricanum(OR = 0.495;95%CI0.292–0.839)reducedtheoccurrenceofadverse
drug events. Conclusions. The use of herbal drugs is high in the HIV-infected population and there is need for pharmacovigilance
programs to recognize the role they play in altering ADR proﬁles.
1.Introduction
Several challenges exist in resource-limited settings between
balancing the cost and toxicity that occurs during antiretro-
viral therapy (ART).Most HIV-infected patients in resource-
limited settings receive a ﬁrst-line triple combination of
lamivudine, nevirapine, and stavudine or zidovudine [1].
Typical examples of ART in these settings include the World
Health Organization prequaliﬁed ﬁxed-dose combinations
of stavudine/lamivudine/nevirapine (D4T/3TC/NVP) and
zidovudine/lamivudine/nevirapine (AZT/3TC/NVP), which
are being widely promoted in highly active antiretroviral
therapy (HAART) “scale-up” programs.
ART is associated with a variety of adverse drug reactions
(ADRs) that can hamper treatment adherence. Particularly,
there is concern about the risk for peripheral neuropathy
with use of stavudine, especially among patients with lower
CD4 cell counts [2] and the risk of rash (including Stevens
Johnson syndrome), hypersensitivity, and life-threatening
hepatotoxicity with use of nevirapine, especially among
women and those with higher CD4 cell counts at initiation
of therapy [3–5]. In Sub-Saharan Africa, diﬀerent incidence
rateshavebeenidentiﬁedforADRsassociatedwithART.The
most commonly evaluated regimen in Sub-Saharan Africa is
theD4T/3TC/NVPcombinationandthishasbeenassociated
with various rates of ADRs in diﬀerent settings [6–13].
Traditional herbal remedies have been used to treat many
ailments in Zimbabwe for many years before the introduc-
tion of orthodox medicines. The advent of HIV/AIDS in
Zimbabwe increased the popularity and use of herbal reme-
dies because antiretroviral drugs were not available at that
time [14]. Studies in South Africa have shown that herbal
remedies are good supplements to antiretroviral therapy be-
cause of their immune boosting properties [15]. A study in
western Uganda found that 38% of HIV-positive patients
used traditional medicines and antiretroviral drugs at the2 AIDS Research and Treatment
same time for the management of HIV infection [16]. The
majorreasonsforuseoftraditionalmedicineswereperceived
additional eﬃcacy, improvement in quality of life, and a
feelingofcontroloverthedisease.Themajorityoftraditional
medicines currently being used by patients have not been
thoroughly researched. The impact of coadministration of
traditional herbal medicine with orthodox medicine has not
yet been fully evaluated and consequently there is a lack of
data which pertains to this subject. Patients are currently
taking herbal medicines with orthodox medicines without
the knowledge of how this aﬀects them.
Researchisrequiredtodeterminefactorswhichaﬀectoc-
currence of ADRs associated with ART. Identiﬁcation of pa-
tients at diﬀerent levels of risk may identify subgroups re-
quiring diﬀerent monitoring intensities. An evaluation of the
potential of the most widely used herbal remedies to interact
with antiretroviral drugs may be helpful in improving the
clinical outcome of patients on ART. It would enable risk
identiﬁcation and assessment, and if necessary, execution of
riskreductionstrategies.Inviewoftheabove,theobjectiveof
this study was to determine the impact of coadministration
of herbal therapy with ART on ADRs.
2.MaterialsandMethods
2.1. Study Site and Population. The study was carried out at
the Family Care Centre (FCC) ART clinic in Harare, Zim-
babwe. The FCC is part of Parirenyatwa Hospital, which is a
major public referral and teaching medical facility. The FCC
is integrated into the outpatient department where patients
receive antiretroviral drugs and treatments for opportunis-
tic infections for free. The results reported are for patients
who had been on ﬁrst-line or alternate-ﬁrst-line ART for at
least 24 weeks. Inclusion criteria were a documented HIV
infection in patients aged 18 years and older on ﬁrst-line or
alternate-ﬁrst-line HAART for at least 24 weeks. THM use
was deﬁned as a daily use of any plant-based extract for a
period of at least 24 weeks.
2.2. Antiretroviral Drug Treatment. The ﬁrst line treatment
available through the government roll-out programme con-
sisted of a triple ﬁxed dose combination of nevirapine
200mg,stavudine30mg,andlamivudine150mgtwicedaily.
Alternate-ﬁrst-linetherapywasavailableforpatientswhodid
not tolerate stavudine and consisted of nevirapine 200mg,
zidovudine 300mg, and lamivudine 150mg twice daily. For
patients concomitantly taking antituberculosis therapy, efa-
virenz (EFV) 600mg once daily at night was prescribed in-
steadof nevirapine asperthenational guidelines. ADRswere
documented after commencement of ARVs.
2.3. Data Collection and Statistical Analysis. Eligible patients
gave written consent before being enrolled into the study.
The FCC pharmacist and peer counselor, who were not
members of the regular ART clinic staﬀ,c o n d u c t e dp a t i e n t
interviews. Patient data that was collected included age,
gender, ethnicity, type of ART regimen, comorbidities, and
herbal medicine use. Interviews took place in either the local
Table 1: Demographic and clinical characteristics of study patients.
Unless speciﬁed, ﬁgures represent frequencies and percentages.
Characteristic N %
Age (mean ± SD) 40.8 9.2
Gender
Male 137 35.3
Female 251 64.7
Comorbidities
Diabetes mellitus 5 1.3
Hypertension 67 17.3
Anaemia 34 8.8
Asthma 21 5.4
Epilespy 4 1.0
Malaria 155 40.0
Tuberculosis 131 33.8
Shingles 125 32.2
ARV regimen
AZT/3TC/EFV 10 2.6
AZT/3TC/NVP 36 9.3
D4T/3TC/EFV 12 3.1
D4T/3TC/NVP 330 85.1
Number of herbs per patient (mean ± SD) 7.9 4.4
language or English, depending on the participant’s prefer-
ence. Data on ADRs was extracted from the ART patient
ﬁles. Potential herbal formulations that could inﬂuence
ADRs were identiﬁed using multivariate linear regression
and logistic regression analysis. An a prioirisigniﬁcance level
of α = 0.05 was used for analyses. A logistic regression mod-
el was used to test whether herbal therapy use aﬀected the
occurrence of ADRs. Three regression models, 1 multiple
linear regression model and 2 logistic regression models,
were run to identify predictors of ADRs. Data analysis was
carriedoutusingtheStatisticalAnalysisSystem(SASVersion
9.2, Cary, North Carolina, USA).
3. Results
3.1. Patient Characteristics. A total of 388 patients were
interviewed,andofthese,381werefoundtobetakingatleast
1h e r b a ld r u g .Table 1 shows the demographic and clinical
characteristics of the study patients. The average age of the
patients was 40.8 ± 9.2 years and the majority were female
(64.7%). The majority (85.1%) of the patients were on the
twice daily regimen of a ﬁxed-dose combination of 30mg
of D4T, 150mg of 3TC, 200mg of NVP. The most common
comorbidities were malaria (40.0%), tuberculosis (33.8%),
shingles (32.2%), and hypertension (17.3%).
3.2. Herbal Drug Use. Table 2 shows the frequency of use of
herbal remedies. The majority of patients (98.2%) were on at
least one indigenous herbal remedy together with their ART
regimen. The most common herbal remedies were Allium
Sativum (72.7%), Bidens pilosa (66.0%), Eucalyptus globulus
(52.3%), Moringa oleifera (44.1%), Lippia javanica (36.3%),
and Peltoforum africanum (34.3%). The results from theAIDS Research and Treatment 3
Table 2: Frequencies of herbal use in study population.
Characteristic N %
Hypoxis hemerocallidea 41 10.6
Dicoma anomala 103 26.6
Aloe vera 108 27.8
Moringa oleifera 171 44.1
Murunguyane† 62 16.0
Musakavakadzi† 13 3.4
Musosote† 15 3.9
Bidens pilosa 256 66.0
Lippia javanica 141 36.3
Peltoforum africanum 133 34.3
Ngoka 11† 30 7.7
Symphytum oﬃcinale 41 10.6
Eucalyptus globules 203 52.3
Allium Sativum 282 72.7
†Scientiﬁc names could not be identiﬁed for these formulations
logistic regression yielded that there was no association be-
tween the comorbidities and the severity of the adverse drug
reactions. The overall multiple regression model for analyz-
ing the data and interpreting the results was signiﬁcant for
this data analysis (Wald’s P value = 0.0055).
A one-way ANOVA test revealed a statistically signiﬁcant
diﬀerence in the average number of herbs each patient was
using and the type of ARV regimen (F = 6.40; df = 3,384;
P = 0.0003). A post hoc analysis revealed that patients on
AZT/3TC/EFV were using fewer herbs (mean = 4.0) compar-
ed to those using other regimens.
Logistic regression was used to identify potential predic-
tors of ADRs, controlling for other variables. There was a
statistically signiﬁcant association between two herbal medi-
cines and the occurrence of ADRs. Patients who used the
indigenous herb, Musakavakadzi, were 75 percent less likely
to develop ADRs compared to patients who did not use the
herb (OR = 0.25; 95% CI: 0.076–0.828; P = 0.023). Similarly,
patients who used Peltoforum africanum were less likely to
develop adverse drug events compared to patients who did
not use the herb (OR = 0.495; 95% CI: 0.292–0.839; P =
0.0091).
3.3. Prevalence of Adverse Drug Reactions. Table 3 shows the
frequency of ADRs reported by patients. A large proportion
of patients experienced at least one ADR during ART treat-
ment (70.4%). The most common ADRs were peripheral
neuropathy (41.8%) and skin rash (26.0%). Peripheral neu-
ropathy was mainly reported by patients on regimens that
included D4T (93.0%). Skin rash was mainly observed with
the NVP-based regimens (88.0%). The other reported ADRs
were lipodystrophy, abdominal pain and gastrointestinal
symptoms (nausea, vomiting, or heartburn).
4. Discussion
TheimpactofherbalmedicineuseontheADRproﬁlesofthe
ﬁrst-line regimens used in Zimbabwe was examined. One of
Table 3: Prevalence of adverse drug reactions in the study patients.
ADR type and severity N %
ADR prevalence 273 70.4
ADR severity (N = 273)
Grade 1 161 41.5
Grade 2 96 24.7
Grade 3 15 3.9
Grade 4 1 0.3
Type of ADRs
Peripheral neuropathy 162 41.8
Skin rash 101 26.0
Lipodystrophy 13 3.4
GI symptoms 28 7.2
the reasons that patients use herbals is to try and alleviate the
discomforts caused by antiretroviral ADRs. A relationship
was observed between the type of antiretroviral regimen
received and the total number of herbs used. Those patients
who were on the regimen containing AZT/3TC/EFV used
fewerherbaltherapieswhencomparedtotheotherregimens.
One possible reason for this could be the decreased rates of
ADRs that are associated with this regimen which decreases
the need for herbal use for managing toxicity. Another
important ﬁnding was the relationship that Musakavakadzi
and Peltoforum africanum had with the rates of ADRs. These
herbal remedies were associated with decreased prevalence
of ADRs, indicating that these herbals might oﬀer some
protection to the patients. It is important to note that 98.2
percent of patients were taking at least one herbal remedy
and with such a high rate of herbal use there is a need to in-
crease research in herbal remedies that have the potential to
inﬂuence treatment outcomes.
This study observed a high prevalence (70.2%) of ADRs
in patients receiving ART. Of note is the high prevalence
of peripheral neuropathy (41.8%) and skin rashes (26.0%).
Skin rash occurrences due to ART were comparable to those
that were observed in other studies [6–10]. Even though the
rates in Zimbabwe are within other reported rates, the pre-
valence of skin rash is relatively higher. Lipodystrophy rates
were lower when compared to studies that were conducted
elsewhere [8, 9, 11]. Similarly, GI symptoms and abdominal
pain rates were comparable to those found in other studies
conducted elsewhere [6, 8, 10].
In light of this high rate of concomitant use of herbal
therapy and ART, there is a potential of altered ART phar-
macokinetics.Someherbalformulationshavebeenidentiﬁed
as having pharmacokinetic interactions with ARVs. Leaf
extracts of Moringa oleifera have been established as having
in vitro CYP3A4 inhibitory activity [17]. Extracts of other
plants such as Sutherlandia and grapefruit juice have been
foundtoalsoinhibitCYP3A4[18].ARTinaresource-limited
setting where herbal use is high needs to make provision for
intensifying the monitoring of herbal medicine use and the
potential eﬀects it can have on therapy [19].
Identiﬁcation of speciﬁc herbal medicines that inﬂuence
ADRs forms a key step in developing further studies that4 AIDS Research and Treatment
will aim to explore the mechanism of action through which
they elicit their action. Unfortunately, because of the limited
laboratory support, the study could only record ADRs that
were clinically apparent. Future studies need to be carried
out that will identify more factors predisposing HIV-positive
patients to toxicities caused by ART.
5. Conclusion
The study observed a high prevalence of concomitant use
of herbal medicines with ART. There was a correlation be-
tween 2 herbal preparations (Musakavakadzi and Peltoforum
africanum) and a low incidence of ADRs. There is a need
to develop pharmacovigilance programs that accommodate
herbal medicines as factors that inﬂuence ADR prevalence.
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